Cellid Co.,Ltd. leads development of anti-cancer immunotherapy.
Original CeliVax Technology
Tumor antigen genes are delivered to autologous B cells and monocytes using a replication-defective recombinant adenoviral vector.
Tumor antigen expressing B cells and monocytes can activate immune responses that kill target cancer cells.
- Tumor antigens for target cancer indications are carefully selected and validated.
- The selected tumor antigen genes are delivered to autologous B cells and monocytes.
- Cellid’s own recombinant adenoviral vector maximizes tumor antigen gene delivery.